GSK settles in fraud case

Share this article:
GlaxoSmithKline will pay $150 million to settle claims it overcharged the U.S. government for anti-nausea drugs Zofran and Kytril.
The government charged Glaxo with engaging in a scheme to inflate the price of Zofran and Kytril for the Medicare and Medicaid programs. The drugs are used to counter nausea experienced by chemotherapy and radiation patients.
The Justice Department said the company charged healthcare providers less for the drugs, knowing the providers would get to keep the difference and would be more likely to prescribe the drugs again.
 "We believe that our price reporting was lawful and was done in good faith," a GSK spokeswoman told the Associated Press, "but we've agreed to this settlement to avoid the delay, expense and uncertainty of litigation."
Share this article:
You must be a registered member of MMM to post a comment.

Email Newsletters

More in News

Five things for Pharma Marketers to know: Friday, August 29

Five things for Pharma Marketers to know: Friday, ...

Takeda closes out a good-news, bad-news kind of week, AstraZeneca adds a new clinical trial for its experimental PD-1, and researchers link a funeral to the Ebola outbreak.

Amgen sends PCSK9 to FDA

Amgen sends PCSK9 to FDA

Evolocumab holds the FDA's first filed biologics license application for the class.

Consultants expect M&A tempo to continue

Consultants expect M&A tempo to continue

PwC anticipates that divestitures will fuel late-2014 deals, but notes that the noise around early deals and the financials don't fully match up.